Register Login

Neumora Therapeutics Inc. (NMRA)

(85% Positive) Neumora Therapeutics Inc. (NMRA) Announces Enrollment Update for life Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 30, 2026, 8:19 a.m.

    📋 Neumora Therapeutics Inc. (NMRA) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:00:19

    Event Type: Clinical Trial Update

    Event Details:

    Neumora Therapeutics Inc. (NMRA) Announces Clinical Trial Update Neumora Therapeutics Inc. (NMRA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: life, plans
    • Clinical Stage: clinical trial
    • Collaboration: Redefining Neuroscience Drug Development
      • Targeting the allosteric site specifically allows for greater selectivity for M4 over other muscarinic sub-types than if targeting the orthosteric site due to binding site conservation To date the pharmacology of agonists targeting the orthosteric site are often thought to display ‘partial’ agonism which could contribute to variable clinical responses PAMs allow for more precise potentiation of M4, maintaining the spatial and temporal signaling dynamics of ACh 1. Digby GJ, et al. J Neurosci. 2012
      • expected in the second quarter of 2026
      • expected in 2026

    🔬 Clinical Development Pipeline (Neumora Therapeutics Inc.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 Major Depressive Disorder ClinicalTrials.gov
    NMRA-335140 DRUG Phase PHASE3 Major Depressive Disorder ClinicalTrials.gov
    NMRA-323511 DRUG Phase PHASE1 Alzheimer's Disease ClinicalTrials.gov
    Non- immersive virtual reality (niVR)-based telerehabilitation home program DEVICE Approved Stroke ClinicalTrials.gov
    NT100 DRUG Phase PHASE2 Recurrent Pregnancy Loss ClinicalTrials.gov
    Post dosing with Placebo OTHER Phase PHASE2 Repeated IVF Failure ClinicalTrials.gov
    Post dosing with NT100 BIOLOGICAL Phase PHASE2 Repeated IVF Failure ClinicalTrials.gov
    NMRA-335140 80 mg DRUG Phase PHASE2 Major Depressive Episode Associated With Bipolar II Disorder ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Neumora Therapeutics Inc.
    • Ticker Symbol: NMRA

Search

News categories